title: Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.
abstract: In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
authors.affiliation: Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. giovanni.schifitto@ctcc.rochester.edu
authors.forename: G
authors.initials: G
authors.lastname: Schifitto
authors.forename: D R
authors.initials: DR
authors.lastname: Peterson
authors.forename: J
authors.initials: J
authors.lastname: Zhong
authors.forename: H
authors.initials: H
authors.lastname: Ni
authors.forename: K
authors.initials: K
authors.lastname: Cruttenden
authors.forename: M
authors.initials: M
authors.lastname: Gaugh
authors.forename: H E
authors.initials: HE
authors.lastname: Gendelman
authors.forename: M
authors.initials: M
authors.lastname: Boska
authors.forename: H
authors.initials: H
authors.lastname: Gelbard
mesh_terms: D015526:AIDS Dementia Complex / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D014635:Valproic Acid / Q000627:therapeutic use*
chemical_list: D044966:Anti-Retroviral Agents; D014635:Valproic Acid